BRANY Licenses its Proprietary Clinical Trial Management System to Tech Software INC/IRB Manager
BRANY (Biomedical Research Alliance of New York) has licensed its proprietary SMART (Study Management and Revenue Tracking) system to Tech Software, Inc., an information technology company that currently offers IRBManager, a fully Web-based software product that supports the administration of institutional review boards at hospitals throughout the country.
The BRANY SMART system is a clinical study management and revenue tracking system that allows study sites to develop study budgets and conduct cost analyses utilizing pricing information stored within the database. Users can also manage and store regulatory documents. The Web-based software-as-a-service (SaaS) also allows clients to track patient encounters, revenue, and accounts receivables. The SMART system, which is 21 CFR 11 ready, gives clinical research sites, research administration, and clinical trial offices the ability to develop their own customized work flows to track and monitor new study opportunities as they progress through a site or hospital’s internal review process. This includes budget, contract, conflict of interest, and IRB review. The SMART system also tracks enrollment against the study and includes integration with Tech’s IRBManager solution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
